Committed to fostering collaborative and productive commercial partnerships
With a track record of successful product- and technology-based collaborations with top-tier pharmaceutical and biotechnology companies, we are a proven industry partner focused on leveraging our capabilities to form long-lasting and productive relationships.
We are highly motivated to build strategic alliances that will help to improve patients’ lives by creating and developing innovative and differentiated antibody-based therapeutics.
Standing together—moving forward
Our quest to develop the next generation of antibody therapeutics recognizes the inherent value in working with resourceful and like-minded partners.
By partnering to enable access to third-party technologies and antibody-based products, we facilitate development of first-in-class or best-in-class antibody therapies and work to transform the future of cancer treatment.
In addition to cancer, we may consider partnership opportunities to address any disease area where antibody-based therapies may be effective, including autoimmune conditions, inflammation, central nervous system conditions and infectious diseases.
During clinical development of our proprietary antibody products, we identify potential partners that will work with us in various ways to enable the full commercial potential of these products to be realized.
Transform the future of cancer treatment with us.
ESMO (European Society for Medical Oncology) Annual Meeting
SITC (Society for Immunotherapy of Cancer) Annual Meeting
ASH (American Society of Hematology) Annual Meeting
Partners in science
See how our collaborative spirit drives our partnerships
Turning insights into medicine
See the results of innovation that is rooted in science
Innovation for the future
We are developing next-generation technologies